Medication info
DuoWell A Tablet 40/5/10 milligrams

DuoWell A Tablet 40/5/10 milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 201900837 · Approved 2019.02.08 · Insurance code 642105390

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time every day (e.g., in the morning). This medicine is administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (telmisartan or amlodipine) be adjusted. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/5mg and rosuvastatin 20mg, the Cmax of rosuvastatin increased approximately 2.3-fold and its AUC increased approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • mixed hyperlipidemia
  • familial homozygous hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy, as well as for patients with hyperlipidemia who require concomitant administration of rosuvastatin calcium. The telmisartan/amlodipine combination helps in controlling blood pressure in essential hypertension, while rosuvastatin, combined with dietary therapy, reduces cholesterol levels and delays the progression of atherosclerosis in lipid disorders such as primary hypercholesterolemia and mixed hyperlipidemia. Additionally, it contributes to reducing the risk of myocardial infarction, stroke, and vascular reconstruction in patients with high cardiovascular risk. Therefore, this medication improves cardiovascular health by managing both hypertension and hyperlipidemia.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time every day (e.g., in the morning). This medicine is administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (telmisartan or amlodipine) be adjusted. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/5mg and rosuvastatin 20mg, the Cmax of rosuvastatin increased approximately 2.3-fold and its AUC increased approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication should not be used in pregnant women. If pregnancy is confirmed, it should be discontinued immediately as it can cause serious damage to the fetus. Individuals allergic to any of the active ingredients or components of this medication should not take it. Furthermore, patients with certain hereditary angioedema or a history of angioedema should avoid this medication. Patients with severe liver dysfunction or bile flow problems should not use this medication. Patients with severely impaired kidney function or specific kidney diseases should also exercise caution. Elderly patients, hypotensive patients, those with elevated serum potassium levels, and patients with mild liver dysfunction should use this medication cautiously. This medication may cause musculoskeletal adverse reactions such as myalgia or muscle weakness, so if muscle-related symptoms occur, consultation with a doctor should be made immediately. If muscle enzyme levels rise, discontinuation may be necessary. Liver function tests are important both before and during treatment due to potential liver function abnormalities. This medication may interact with other drugs, so if you are taking any other medications, you must inform your doctor or pharmacist. Breastfeeding women are advised not to take this medication, and if unavoidable, they should stop breastfeeding. It is not recommended for children as safety and efficacy have not been sufficiently established. In case of overdose, symptoms such as hypotension, dizziness, and cardiac arrhythmias may appear, and immediate medical attention should be sought. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Viral upper respiratory infection, conjunctivitis, peripheral edema, chest discomfort, dizziness, abdominal pain, duodenitis, arthralgia, intervertebral disc protrusion, spinal canal stenosis, tinnitus, increased ALT, increased AST, increased ALP, increased γ-GTP, chronic gastritis, hiatal hernia, peripheral edema, dizziness, orthostatic hypotension, low back pain, headache, upper abdominal discomfort, positional vertigo, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastric neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, ear ringing, hearing loss, bad breath, fatty liver, headache, dizziness, malaise, cough, nausea, fatigue, weakness, edema, facial swelling, leg swelling, vascular edema, itching, hypersensitivity reactions, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, low back pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver function abnormalities, liver disease, acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, vascular edema, palpitations, dependency edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory abnormalities, involuntary muscle contractions, anxiety, depression, nervous irritability, allergies, fever, leg pain, lethargy, asthma, bronchitis, shortness of breath, nosebleeds, dermatitis, rash, eczema, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, burning sensation, stiffness, weight gain, weight loss, sexual dysfunction, insomnia, abnormal dreams, depersonalization, shortness of breath, nosebleeds, vascular edema, erythema multiforme, rash, erythematous rash, papular rash, diplopia, eye pain, urinary disturbances, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, gynecomastia, jaundice, hepatitis, Stevens-Johnson syndrome, photosensitivity reactions, toxic epidermal necrolysis, polyneuropathy, memory loss, peripheral neuropathy, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular myasthenia, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, vascular edema, headache, dizziness, edema, flushing, palpitations, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, sensory abnormalities, tremors, dizziness, loss of appetite, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, weakness, low back pain, burning sensation, lethargy, pain, stiffness, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, sexual dysfunction, insomnia, nervous irritability, depression, abnormal dreams, anxiety, depersonalization, shortness of breath, nosebleeds, vascular edema, erythema multiforme, itching, rash, erythematous rash, papular rash, visual disturbances, conjunctivitis, diplopia, eye pain, ear ringing, frequent urination, urinary disturbances, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, gynecomastia, jaundice, elevated liver enzyme levels, leukopenia, confusion, peeling dermatitis, Stevens-Johnson syndrome, photosensitivity reactions, toxic epidermal necrolysis, vascular edema, hypersensitivity reactions, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastric neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, ear ringing, hearing loss, bad breath, fatty liver, chronic gastritis, hiatal hernia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects from light. Additionally, it is important to store the medication at room temperature between 1 and 30 degrees Celsius to ensure safety.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.